pravastatin has been researched along with Uremia in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (33.33) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Furukubo, T; Izumi, S; Kimura, A; Minegaki, T; Nishiguchi, K; Saiki, T; Tachiki, H; Tsujimoto, M; Uchiyama, H; Yamakawa, T; Yoshida, T; Yuki, E | 1 |
| Furukubo, T; Izumi, S; Minegaki, T; Nishiguchi, K; Oda, T; Ogino, H; Shinmoto, T; Tachiki, H; Tsujimoto, M; Uchiyama, H; Yamakawa, T; Yoshida, T | 1 |
| Furukubo, T; Hatozaki, D; Izumi, S; Minegaki, T; Nishiguchi, K; Shima, D; Tsujimoto, M; Yamakawa, T; Yokota, H | 1 |
| Deguchi, T; Endou, H; Kusuhara, H; Otagiri, M; Sugiyama, Y; Takadate, A | 1 |
| Emoto, M; Inoue, T; Kawasaki, K; Konishi, T; Morii, H; Nishizawa, Y; Shoji, T; Tabata, T | 1 |
| Inoue, T; Morii, H; Nishizawa, Y; Shoji, T; Tabata, T | 1 |
1 trial(s) available for pravastatin and Uremia
| Article | Year |
|---|---|
Reduction of intermediate density lipoprotein by pravastatin in hemo- and peritoneal dialysis patients.
Topics: Apolipoproteins; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Female; Humans; Lipase; Lipoprotein Lipase; Lipoproteins; Lipoproteins, IDL; Liver; Male; Middle Aged; Peritoneal Dialysis, Continuous Ambulatory; Phosphatidylcholine-Sterol O-Acyltransferase; Pravastatin; Renal Dialysis; Triglycerides; Uremia | 1995 |
5 other study(ies) available for pravastatin and Uremia
| Article | Year |
|---|---|
Effects of Uremic Serum Residue on OATP1B1- and OATP1B3-Mediated Pravastatin Uptake in OATP-Expressing HEK293 Cells and Human Hepatocytes.
Topics: Biological Transport; Cells, Cultured; HEK293 Cells; Hepatocytes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Liver-Specific Organic Anion Transporter 1; Pravastatin; Solute Carrier Organic Anion Transporter Family Member 1B3; Toxins, Biological; Uremia | 2019 |
Uremic toxins enhance statin-induced cytotoxicity in differentiated human rhabdomyosarcoma cells.
Topics: Apoptosis; Cell Differentiation; Cell Line, Tumor; Cell Survival; Drug Synergism; Furans; Hippurates; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indican; Indoleacetic Acids; Pravastatin; Propionates; Rhabdomyosarcoma; Simvastatin; Toxins, Biological; Uremia | 2014 |
Influence of serum in hemodialysis patients on the expression of intestinal and hepatic transporters for the excretion of pravastatin.
Topics: Biological Transport; Caco-2 Cells; Carcinoma, Hepatocellular; Cell Line, Tumor; Down-Regulation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intestinal Absorption; Kidney Failure, Chronic; Liver; Liver Neoplasms; Liver-Specific Organic Anion Transporter 1; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Organic Anion Transporters; Pravastatin; Renal Dialysis; RNA, Messenger; Uremia | 2012 |
Characterization of uremic toxin transport by organic anion transporters in the kidney.
Topics: Animals; DNA, Complementary; GABA Modulators; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Tubules, Proximal; LLC-PK1 Cells; Male; Organ Culture Techniques; Organic Anion Transport Protein 1; Organic Anion Transporters, Sodium-Independent; p-Aminohippuric Acid; Penicillin G; Pravastatin; Rats; Rats, Sprague-Dawley; Swine; Toxins, Biological; Transfection; Uremia | 2004 |
Effects of lipid-lowering drugs on intermediate-density lipoprotein in uremic patients.
Topics: Cholesterol, LDL; Cholesterol, VLDL; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipoprotein(a); Lipoproteins; Lipoproteins, VLDL; Niceritrol; Peritoneal Dialysis, Continuous Ambulatory; Phenoxyacetates; Pravastatin; Renal Dialysis; Uremia | 1999 |